Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Atai的DMt抗抑鬱藥物顯示出潛力，準備進入第二階段臨床試驗並與大型製藥公司合作。
Atai Life Sciences (NASDAQ:ATAI) announced promising preliminary results on Tuesday for its DMT-based depression therapy, VLS-01. As BioSpace reported, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with treatment-resistant depression.
Atai Life Sciences (NASDAQ: ATAI)在週二發佈了其基於DMt治療抑鬱症的VLS-01的令人期待的初步結果。正如BioSpace報道的那樣，這些來自一項Phase Ib研究的發現使Atai有望於今年晚些時候進行第二期試驗，針對的是患有難治性抑鬱症的患者。
Promising Phase Ib Results For DMT-Based Depression Therapy
基於DMt治療抑鬱症的相 Phase Ib 的有望結果
VLS-01, an oral formulation of N,N-dimethyltryptamine (DMT), is designed to be administered via a buccal film applied to the lining of the cheek. This delivery method aims to induce a short, controlled psychedelic experience, potentially offering relief to those suffering from treatment...
VLS-01 是一種口服N，N-二甲基色胺（DMT）製劑，旨在通過貼在口腔內側的頰膜片形...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間